the aid library

National Antenatal Sentinel HIV Survey Key Findings, South Africa 2017

south (2019) CC

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov ... more

Breast and cervical cancer screening services in Malawi: a systematic review

Pittalis, C.; Panteli, E.; Schouten, E. et al. BMC (2020) CC2

To identify and to assess factors enhancing or hindering the delivery of breast and cervical cancer screening services in Malawi with regard to accessibility, uptake, acceptability and effectiveness. Systematic review of published scientific evidence. A search of six bibliographic databases and gre ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Stratégie d’utilisation des substances naturelles dans la prise en charge des personnes vivant avec le VIH : expérience du Burkina Faso

Nikiéma J. B., K. Djierro, J. Simpore et al. Ethnopharmacologia (2009) C2

Au Burkina Faso, les personnes vivant avec le VIH (PvVIH) ont régulièrement recours à des substances naturelles pour traiter certaines infections opportunistes. C’est ainsi que le suc des feuilles fraîches de Mitracarpus scaber Zucc. ex Schult. & Schult. f. (Rubiaceae) et de Senna alata (L.) R ... more

APCA Standards for Providing Quality Palliative Care Across Africa

African Palliative Care Association (2018) CC

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

Strengthening the collection, analysis and use of health workforce data and information: a handbook

World Health Organisation (WHO) (2023) C_WHO

Access to health workers who are fit for purpose, motivated and protected is a fundamental force of health service delivery and the achievement of universal health coverage and the health and health-related Sustainable Development Goals. Data and knowledge of the distribution, skill mix and future d ... more

THE NATIONAL PROTOCOL FOR TREATMENT OF SUBSTANCE USE DISORDERS IN KENYA

Ministry of Health, Republic of Kenya (2017) C2

Polio Laboratory Manual

World Health Organization (2004) C_WHO

Young People and Alcohol. A resource book

Yvonne Bonomo, Cornelius Goos, John Howard et al. World Health Organization, Western Pacific Region (2015) C_WHO

Handbook of Humanitarian Health Care Logistics 2nd edition

McGuire, George (2011) CC

Handbook of HUMANITARIAN HEALTH CARE LOGISTICS Designing the Supply Network and Managing the Flows of Information and Health Care Goods in Humanitarian Assistance during Complex Political Emergencies

COVID-19 Appeal: South Sudan Preparedness and Response Plan - July 2020 - June 2021

International Organization for Migration IOM (2020) C1

Preventing disease through healthy environments: a global assessment of the burden of disease from environmental risks

Prüss-Ustün, A.; J. Wolf, C. Corvalán, et al. World Health Organization WHO (2018) C_WHO

The main message emerging from this new comprehensive global assessment is that premature death and disease can be prevented through healthier environments – and to a significant degree. Analysing the latest data on the environment-disease nexus and the devastating impact of environmental hazards ... more

The Logistics Handbook - A Practical Guide for the Supply Chain Management of Health Commodities

USAID Deliver (2011) C1

This resource offers practical guidance in managing the supply chain, with emphasis on health comodities. The handbook is particularly useful for program managers who design, manage, and assess logistics system for health program. The document includes detailed information about the design and imple ... more

European nurse: Information and communication guide on microbes

European specialist nurse organisation (ESN) (2020) C2

This manual addresses all the issues. It focus on the cycle of microbes, antibiotics, vaccination, AMR, infection prevention and control. It will support nurses on better action and also on communication towards their patients and families.